Andrew Wang, MD
Cardiovascular Disease · Durham, NCNPI 1063596930
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 86.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $53,050 and has fallen 91.6% since, to $4,438 in 2025. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $1004.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$100K
- Ipsen Biopharmaceuticals, Inc$7K
- Astrazeneca UK Limited$4K
- Edwards Lifesciences$2K
- Medtronic$1K
- Abbott$1K
- plus $892 from 6 others
Across 92 payments — averaging $21,806 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.7M
- Abbott$244K
- Lexicon Pharmaceuticals, Inc.$62K
- Ipsen Biopharmaceuticals, Inc$4K
- Ipsen Bioscience Inc.$750
What the payments were for
- Consulting fees$65,49257%
- Speaking & faculty fees$43,14337%
- Travel & lodging$4,5374%
- Food & beverage$2,3442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 58 | $99,977 |
| Ipsen Biopharmaceuticals, Inc | 2 | $6,600 |
| Astrazeneca UK Limited | 12 | $4,175 |
| Edwards Lifesciences | 8 | $1,524 |
| Medtronic | 14 | $1,264 |
| Abbott | 12 | $1,084 |
| Pfizer | 4 | $445 |
| Bristol Myers Squibb | 1 | $300 |
| Genentech USA, Inc. | 1 | $55 |
| Biosense Webster, Inc. | 1 | $34 |
| Lilly USA, LLC | 1 | $33 |
| Novartis | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,516 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 100 | $884,473 |
| EliquisApixaban | 94 | $69,815 |
| EntrestoSacubitril/Valsartan | 68 | $56,771 |
| JardianceEmpagliflozin | 45 | $30,667 |
| Metoprolol Succinate | 203 | $2,652 |
| Losartan Potassium | 135 | $1,192 |
| Potassium Chloride | 30 | $1,030 |
| Spironolactone | 87 | $864 |
| Carvedilol | 67 | $793 |
| Nebivolol Hcl | 16 | $616 |
| Atorvastatin Calcium | 57 | $601 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 39 | $594 |
| Lisinopril | 83 | $544 |
| Valsartan | 11 | $457 |
| Furosemide | 90 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $99,977 | $884,473100 claims |
| PfizerEliquis | $445 | $69,81594 claims |
| NovartisEntresto | $25 | $56,77168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Durham
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Robert MentzDurham$489K
- Adrian HernandezDurham$409K
- Neha PagidipatiDurham$301K
- Joseph KissloDurham$283K
- Mitchell KrucoffDurham$281K
- Ankeet BhattDurham$258K
- Christopher GrangerDurham$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.